Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8506 |
High Similarity |
NPD6234 |
Discontinued |
0.8444 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8357 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8258 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8258 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8258 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8137 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8108 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8065 |
Intermediate Similarity |
NPD37 |
Approved |
0.8056 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8056 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7937 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7902 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.784 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7832 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7832 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7826 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7808 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7808 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7808 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7778 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7778 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7733 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD1091 |
Approved |
0.763 |
Intermediate Similarity |
NPD228 |
Approved |
0.7619 |
Intermediate Similarity |
NPD7240 |
Approved |
0.759 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.758 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7562 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7562 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7552 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7544 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7532 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7481 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7432 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7413 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7403 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7396 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7394 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7394 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7391 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7386 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7386 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7372 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7347 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7337 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7294 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7285 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7278 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7256 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7255 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7248 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7239 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7212 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7209 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7197 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7195 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7195 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7192 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7192 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7179 |
Intermediate Similarity |
NPD4237 |
Approved |
0.717 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD27 |
Approved |
0.716 |
Intermediate Similarity |
NPD2489 |
Approved |
0.716 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7134 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7134 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7133 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7126 |
Intermediate Similarity |
NPD7312 |
Approved |
0.7126 |
Intermediate Similarity |
NPD7313 |
Approved |
0.7126 |
Intermediate Similarity |
NPD7310 |
Approved |
0.7126 |
Intermediate Similarity |
NPD7311 |
Approved |
0.7123 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7119 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.711 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7105 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7101 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7101 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7095 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7086 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD7309 |
Approved |
0.7081 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD4749 |
Approved |
0.707 |
Intermediate Similarity |
NPD3060 |
Approved |
0.707 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7069 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7069 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7059 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD709 |
Approved |
0.7042 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7042 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7041 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7041 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7035 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7034 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7032 |
Intermediate Similarity |
NPD5588 |
Approved |
0.703 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.703 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7029 |
Intermediate Similarity |
NPD4577 |
Approved |
0.7029 |
Intermediate Similarity |
NPD4578 |
Approved |
0.7029 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7027 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7025 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7019 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7011 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD4663 |
Approved |
0.6993 |
Remote Similarity |
NPD4140 |
Approved |
0.6987 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6981 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6968 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6968 |
Remote Similarity |
NPD4536 |
Approved |
0.6968 |
Remote Similarity |
NPD4538 |
Approved |
0.6966 |
Remote Similarity |
NPD5691 |
Approved |
0.6966 |
Remote Similarity |
NPD7906 |
Approved |
0.6966 |
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6957 |
Remote Similarity |
NPD290 |
Approved |
0.695 |
Remote Similarity |
NPD7843 |
Approved |
0.6944 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6944 |
Remote Similarity |
NPD7296 |
Approved |
0.6943 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6943 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6943 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6941 |
Remote Similarity |
NPD6071 |
Discontinued |
0.6941 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6939 |
Remote Similarity |
NPD3092 |
Approved |
0.6937 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD5494 |
Approved |
0.6918 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6914 |
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD7095 |
Approved |
0.6903 |
Remote Similarity |
NPD6353 |
Approved |
0.6903 |
Remote Similarity |
NPD4097 |
Suspended |
0.6903 |
Remote Similarity |
NPD2157 |
Approved |
0.6903 |
Remote Similarity |
NPD6653 |
Approved |
0.6894 |
Remote Similarity |
NPD7041 |
Phase 2 |
0.6894 |
Remote Similarity |
NPD1511 |
Approved |
0.6894 |
Remote Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.6892 |
Remote Similarity |
NPD2232 |
Approved |
0.6892 |
Remote Similarity |
NPD2233 |
Approved |
0.6892 |
Remote Similarity |
NPD2230 |
Approved |
0.689 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6886 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6882 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6879 |
Remote Similarity |
NPD2438 |
Suspended |
0.6875 |
Remote Similarity |
NPD6190 |
Approved |
0.6875 |
Remote Similarity |
NPD5241 |
Discontinued |
0.6863 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6852 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6852 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6836 |
Remote Similarity |
NPD8313 |
Approved |
0.6836 |
Remote Similarity |
NPD8312 |
Approved |
0.6835 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6829 |
Remote Similarity |
NPD4210 |
Discontinued |
0.6824 |
Remote Similarity |
NPD4666 |
Phase 3 |
0.6821 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6821 |
Remote Similarity |
NPD4624 |
Approved |
0.6818 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6818 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6815 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6815 |
Remote Similarity |
NPD3020 |
Approved |
0.6815 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6813 |
Remote Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.681 |
Remote Similarity |
NPD1512 |
Approved |
0.681 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6805 |
Remote Similarity |
NPD5604 |
Discontinued |
0.68
|
Remote Similarity |
NPD1283 |
Approved |